Figure 1. Research Method Flow Chart 11
Figure 2. Breakdown of Primary Research 13
Figure 3. Bottom-up Approach and Top-down Approach for Market Estimation 15
Figure 4. North America Market Forecast in Optimistic, Conservative and Balanced Perspectives, 2019-2030 17
Figure 5. North America Pharmacogenomics Market, 2019-2030, $ mn 20
Figure 6. An Overall Process of How Pharmacogenomics Functions in a Clinical Practice 22
Figure 7. Impact of COVID-19 on Business 24
Figure 8. Primary Drivers and Impact Factors of North America Pharmacogenomics Market 26
Figure 9. World Top 10 Causes of Deaths, 2016 29
Figure 10. Primary Restraints and Impact Factors of North America Pharmacogenomics Market 30
Figure 11. Consecutive Phases and Associated Challenges in Pharmacogenomics 32
Figure 12. Investment Opportunity Analysis 34
Figure 13. Porter’s Fiver Forces Analysis of North America Pharmacogenomics Market 37
Figure 14. Breakdown of North America Pharmacogenomics Market by Service, 2019-2030, % of Revenue 41
Figure 15. North America Addressable Market Cap in 2020-2030 by Service, Value ($ mn) and Share (%) 42
Figure 16. North America Pharmacogenomics Market: Genotyping, 2019-2030, $ mn 43
Figure 17. North America Pharmacogenomics Market: SNP Identification, 2019-2030, $ mn 44
Figure 18. North America Pharmacogenomics Market: Diagnostics, 2019-2030, $ mn 45
Figure 19. North America Pharmacogenomics Market: Other Services, 2019-2030, $ mn 47
Figure 20. Breakdown of North America Pharmacogenomics Market by Technology, 2019-2030, % of Sales Revenue 48
Figure 21. North America Addressable Market Cap in 2020-2030 by Technology, Value ($ mn) and Share (%) 49
Figure 22. North America Pharmacogenomics Market: Polymerase Chain Reaction (PCR), 2019-2030, $ mn 50
Figure 23. North America Pharmacogenomics Market: Microarray, 2019-2030, $ mn 51
Figure 24. North America Pharmacogenomics Market: Sequencing, 2019-2030, $ mn 52
Figure 25. North America Pharmacogenomics Market: Electrophoresis, 2019-2030, $ mn 53
Figure 26. North America Pharmacogenomics Market: Mass Spectrometry, 2019-2030, $ mn 54
Figure 27. North America Pharmacogenomics Market: Other Technologies, 2019-2030, $ mn 55
Figure 28. Breakdown of North America Pharmacogenomics Market by Application, 2019-2030, % of Sales Revenue 56
Figure 29. North America Addressable Market Cap in 2020-2030 by Application, Value ($ mn) and Share (%) 57
Figure 30. North America Pharmacogenomics Market: Oncology, 2019-2030, $ mn 58
Figure 31. North America Pharmacogenomics Market: Infectious Diseases, 2019-2030, $ mn 59
Figure 32. North America Pharmacogenomics Market: Neurology/Psychiatry, 2019-2030, $ mn 60
Figure 33. North America Pharmacogenomics Market: Cardiovascular, 2019-2030, $ mn 62
Figure 34. North America Pharmacogenomics Market: Pain Management, 2019-2030, $ mn 63
Figure 35. North America Pharmacogenomics Market: Other Applications, 2019-2030, $ mn 64
Figure 36. Breakdown of North America Pharmacogenomics Market by End User, 2019-2030, % of Revenue 65
Figure 37. North America Addressable Market Cap in 2020-2030 by End User, Value ($ mn) and Share (%) 66
Figure 38. North America Pharmacogenomics Market: Hospitals and Clinics, 2019-2030, $ mn 67
Figure 39. North America Pharmacogenomics Market: Pharmaceutical Companies, 2019-2030, $ mn 68
Figure 40. North America Pharmacogenomics Market: Research Institutes, 2019-2030, $ mn 69
Figure 41. Breakdown of North America Pharmacogenomics Market by Country, 2019 and 2030, % of Revenue 71
Figure 42. Contribution to North America 2020-2030 Cumulative Revenue by Country, Value ($ mn) and Share (%) 72
Figure 43. U.S. Pharmacogenomics Market, 2019-2030, $ mn 74
Figure 44. Canada Pharmacogenomics Market, 2019-2030, $ mn 77
Figure 45. Pharmacogenomics Market in Mexico, 2015-2030, $ mn 79
Figure 46. Growth Stage of North America Pharmacogenomics Industry over the Forecast Period 81
North America pharmacogenomics market is expected to grow by 7.7% annually in the forecast period and reach $5,451.4 million by 2030 driven by increase in adoption of personalized medicine and surge in usage of pharmacogenomics for drug discovery and development amid COVID-19 pandemic. Highlighted with 28 tables and 46 figures, this 117-page report “North America Pharmacogenomics Market 2020-2030 by Service (Genotyping, SNP, Diagnostics), Technology (PCR, Microarray, Sequencing, Electrophoresis, MS), Application, End User, and Country: Trend Forecast and Growth Opportunity” is based on a comprehensive research of the entire North America pharmacogenomics market and all its sub-segments through extensively detailed classifications. Profound analysis and assessment are generated from premium primary and secondary information sources with inputs derived from industry professionals across the value chain. The report is based on studies on 2015-2019 and provides forecast from 2020 till 2030 with 2019 as the base year. (Please note: The report will be updated before delivery so that the latest historical year is the base year and the forecast covers at least 5 years over the base year.) In-depth qualitative analyses include identification and investigation of the following aspects: • Market Structure • Growth Drivers • Restraints and Challenges • Emerging Product Trends & Market Opportunities • Porter’s Fiver Forces The trend and outlook of North America market is forecast in optimistic, balanced, and conservative view by taking into account of COVID-19. The balanced (most likely) projection is used to quantify North America pharmacogenomics market in every aspect of the classification from perspectives of Service, Technology, Application, End User, and Country. Based on Service, the North America market is segmented into the following sub-markets with annual revenue for 2019-2030 included in each section. • Genotyping • SNP Identification • Diagnostics • Other Services Based on Technology, the North America market is segmented into the following sub-markets with annual revenue for 2019-2030 included in each section. • Polymerase Chain Reaction (PCR) • Microarray • Sequencing • Electrophoresis • Mass Spectrometry • Other Technologies Based on Application, the North America market is segmented into the following sub-markets with annual revenue for 2019-2030 included in each section. • Oncology • Infectious Diseases • Neurology/Psychiatry • Cardiovascular • Pain Management • Other Applications Based on End User, the North America market is segmented into the following sub-markets with annual revenue for 2019-2030 included in each section. • Hospitals and Clinics • Pharmaceutical Companies • Research Institutes Geographically, the following national/local markets are fully investigated: • U.S. • Canada • Mexico Detailed analysis and annual revenue 2019-2030 are available for each key national market. The breakdown of key national markets by Service, Technology, and Application over the forecast years are also included. The report also covers current competitive scenario and the predicted trend; and profiles key vendors including market leaders and important emerging players. Specifically, potential risks associated with investing in North America pharmacogenomics market are assayed quantitatively and qualitatively through GMD’s Risk Assessment System. According to the risk analysis and evaluation, Critical Success Factors (CSFs) are generated as a guidance to help investors & stockholders identify emerging opportunities, manage and minimize the risks, develop appropriate business models, and make wise strategies and decisions. Key Players (this may not be a complete list and extra companies can be added upon request): 23andMe, Inc. Abbott Laboratories Admera Health, LLC Agena Biosciences, Inc. Astra Zeneca PLC Bayer AG Becton, Dickinson and Company Cancer Genetics, Inc. Dynamic DNA Laboratories Empire Genomics LLC F. Hoffmann-La Roche Ltd geneOmbio Technologies Pvt Ltd. Genomic Health, Inc. Illumina, Inc. Laboratory Corporation of America Holdings Myriad Genetics Inc. Oneome LLC Opko Health, Inc. Pathway Genomics Corporation QIAGEN N.V. Quest Diagnostics Incorporated Teva Pharmaceuticals Industries Ltd. Thermo Fisher Scientific Inc. Transgenomic, Inc. (Please note: The report will be updated before delivery so that the latest historical year is the base year and the forecast covers at least 5 years over the base year.)
Read More